8-K: Capricor Reports Q4/FY25 Results, Deramiocel BLA Under FDA Review

Capricor Therapeutics announced its Q4 and full-year 2025 financial results, highlighting the ongoing FDA review of its Deramiocel BLA for Duchenne muscular dystrophy with an August 22, 2026 PDUFA date.

Summary

• The Biologics License Application (BLA) for Deramiocel, targeting Duchenne muscular dystrophy (DMD), is under review by the U.S. FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026.
• The pivotal HOPE-3 Phase 3 trial achieved its primary endpoint (Performance of the Upper Limb, PUL v2.0) and a key secondary cardiac endpoint (Left Ventricular Ejection Fraction, LVEF), both demonstrating statistical significance (p=0.03 and p=0.04, respectively).
• Late-breaking HOPE-3 data presented at MDA 2026 showed a significant reduction in myocardial fibrosis (p=0.022) and greater than 100% attenuation of expected cardiac decline in patients with baseline cardiomyopathy (p=0.017).
• The San Diego GMP manufacturing facility is operational and successfully completed an FDA Pre-License Inspection, positioning it to support a potential commercial launch, with further expansion underway.
• Capricor's common stock was uplisted to the Nasdaq Global Select Market, Nasdaq's highest listing tier, on March 9, 2026.
• Cash, cash equivalents, and marketable securities totaled approximately $318.1 million as of December 31, 2025, a significant increase from $151.5 million as of December 31, 2024.
• The company reported $0 in revenue for both the fourth quarter and full year ended December 31, 2025, compared to $11.1 million and $22.3 million for the corresponding periods in 2024, as prior milestone payments were fully recognized by December 31, 2024.
• Net loss for the fourth quarter of 2025 was approximately $30.2 million ($0.62 per share), compared to a net loss of approximately $7.1 million ($0.16 per share) for the fourth quarter of 2024.
• Net loss for the full year 2025 was approximately $105.0 million ($2.26 per share), compared to a net loss of approximately $40.5 million ($1.15 per share) for the full year 2024.
• Total operating expenses increased to approximately $29.2 million for Q4 2025 (from $18.8 million in Q4 2024) and $108.1 million for FY 2025 (from $64.8 million in FY 2024).
• The current cash balance is expected to support operations through 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as largely positive due to significant clinical and regulatory progress for Deramiocel, a strong cash position, and uplisting, despite the expected increase in net loss due to lack of milestone revenue and increased operational spend for commercialization.

Positives

• Deramiocel's Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) is under active FDA review, with a PDUFA target action date of August 22, 2026.
• The pivotal HOPE-3 Phase 3 trial successfully met its primary endpoint (PUL v2.0, p=0.03) and a key secondary cardiac endpoint (LVEF, p=0.04), demonstrating Deramiocel's efficacy.
• Late-breaking HOPE-3 data showed significant reduction in myocardial fibrosis (p=0.022) and over 100% attenuation of expected cardiac decline in cardiomyopathy patients (p=0.017), reinforcing cardiac benefits.
• The San Diego GMP manufacturing facility is operational and successfully completed an FDA Pre-License Inspection, indicating readiness for potential commercial launch.
• Cash, cash equivalents, and marketable securities significantly increased to approximately $318.1 million as of December 31, 2025, from $151.5 million at December 31, 2024, providing a strong financial position.
• The strengthened balance sheet is projected to fund operations through 2027, offering financial stability.
• Capricor's common stock was uplisted to the Nasdaq Global Select Market on March 9, 2026, enhancing visibility and prestige.
• Preliminary data from the NIAID-sponsored Phase 1 clinical trial for the StealthX exosome-based vaccine platform indicate a favorable safety profile.

Negatives

• Revenues for both the fourth quarter and full year 2025 were $0, a substantial decrease from $11.1 million and $22.3 million respectively in 2024, due to the full recognition of prior milestone payments.
• Net loss for the fourth quarter of 2025 increased significantly to approximately $30.2 million ($0.62 per share) from $7.1 million ($0.16 per share) in the prior year period.
• Net loss for the full year 2025 increased to approximately $105.0 million ($2.26 per share) from $40.5 million ($1.15 per share) in the prior year.
• Total operating expenses rose considerably to approximately $29.2 million for Q4 2025 (from $18.8 million in Q4 2024) and $108.1 million for FY 2025 (from $64.8 million in FY 2024), reflecting increased R&D and commercialization costs.

Risks

• The 'Cautionary Note Regarding Forward-Looking Statements' refers to risks outlined in previous 10-K and 10-Q filings, including those related to the efficacy, safety, and intended utilization of product candidates, the initiation, conduct, size, timing, and results of clinical trials, the pace of enrollment of clinical trials, plans regarding regulatory filings, future research and clinical trials, regulatory developments, manufacturing capabilities, potential delays or unsuccessful regulatory inspections, and the ability to achieve product milestones and receive milestone payments from commercial partners.

Future Outlook

The company expects its current cash, cash equivalents, and marketable securities of approximately $318.1 million to be sufficient to cover anticipated expenses and capital requirements through 2027. This outlook excludes potential additional milestone payments under the Commercialization and Distribution Agreements with Nippon Shinyaku, as well as any strategic use of capital not currently in the company's base case planning assumptions. Final results for the NIAID-sponsored Phase 1 StealthX clinical trial are expected in the second quarter of 2026.

Management Comments

• "Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD)."
• "With the FDA review of our BLA underway and a PDUFA target action date of August 22, 2026, our highest priority is execution, including working closely with the Agency, preparing for potential launch, and continuing to build the capabilities for a commercial-stage company."
• "Recent late-breaking data presented at the 2026 MDA Clinical & Scientific Conference further reinforced the strength of the program, highlighting Deramiocel's impact on both cardiac and skeletal muscle function in Duchenne."
• "These findings build on the positive topline results from the Phase 3 HOPE-3 study and reinforce Deramiocel's potential to become a first-in-class therapy for Duchenne designed to address both the skeletal and cardiac manifestations of this devastating disease."
• "At the same time, we remain focused on advancing our exosome platform and expanding the long-term potential of our pipeline. Supported by a strong balance sheet, we believe we are well positioned to execute on these priorities and deliver meaningful value for patients, families, and shareholders."

Industry Context

StockSavvy.ai notes that the ongoing FDA review of Deramiocel for DMD, coupled with positive Phase 3 data demonstrating both skeletal and cardiac benefits, positions Capricor as a significant player in the rare disease biotechnology sector. The PDUFA date of August 22, 2026, represents a critical near-term catalyst in the competitive landscape for DMD therapies, where effective treatments for both functional decline and cardiac complications are highly sought after. The company's exosome platform development also indicates a broader strategic focus beyond its lead candidate.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or results within the industry.

Stakeholder Impact

• Shareholders: Potential for significant value creation from Deramiocel approval and commercialization, strengthened financial position, and increased visibility from Nasdaq Global Select Market uplisting. Dilution from recent capital raises.
• Patients (DMD): Hope for a new, potentially first-in-class therapy addressing both skeletal and cardiac manifestations of Duchenne muscular dystrophy.
• Employees: Increased activity and potential for growth as the company transitions towards commercialization.
• Regulatory Authorities (FDA): Ongoing engagement through the BLA review process and manufacturing inspections.

Next Steps

• Work closely with the FDA during the BLA review process for Deramiocel.
• Prepare for the potential commercial launch of Deramiocel.
• Continue manufacturing expansion to increase capacity for anticipated demand following potential approval.
• Expect final results for the NIAID-sponsored Phase 1 StealthX clinical trial in the second quarter of 2026.
• Participate in the 38th Annual Roth Conference from March 22-24, 2026.

Key Dates

Recommendation

While the clinical and regulatory progress for Deramiocel is highly positive and the company has a strong cash runway, the significant increase in net loss and zero revenue for 2025 reflect the pre-commercial stage and high R&D costs. The stock is likely to be volatile around the PDUFA date. A 'hold' recommendation allows investors to maintain exposure to the potential upside of approval while acknowledging the current financial burn and the inherent risks of a biotechnology company awaiting regulatory decision.

Keywords

Capricor Therapeutics, CAPR, Duchenne muscular dystrophy, DMD, Deramiocel, BLA, FDA review, PDUFA, HOPE-3, Phase 3 trial, clinical data, cardiac function, skeletal muscle, GMP manufacturing, Nasdaq Global Select Market, financial results, Q4 2025, FY 2025, biotechnology, rare diseases, exosome platform, StealthX